NYU Langone Among First to Enroll Patients in Clinical Trial for COVID-19 Monoclonal Antibody Treatment
June 02, 2020
June 02, 2020
NEW YORK, June 2 -- NYU Langone Health, an academic medical center affiliated with New York University, issued the following news release:
The first patients were treated as part of a clinical trial testing whether an antibody therapy can safely reduce 2019 coronavirus disease (COVID-19) severity. The experimental treatment consists of identical copies of an antibody, a blood protein related to those that occur naturally as part of the human immune system, researchers say.
The first patients were treated as part of a clinical trial testing whether an antibody therapy can safely reduce 2019 coronavirus disease (COVID-19) severity. The experimental treatment consists of identical copies of an antibody, a blood protein related to those that occur naturally as part of the human immune system, researchers say.